Written question asked by Fred Thomas (Labour) on Monday, 8 September 2025, in the House of Commons. It was due for an answer on Thursday, 11 September 2025 (named day). A holding answer was provided on Monday, 15 September 2025. A substantive answer was provided by Zubir Ahmed (Labour) on Monday, 15 September 2025 on behalf of the Department of Health and Social Care.
Fampridine
- Question
-
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the National Institute for Health and Care Excellence on the prescription of Fampridine as a treatment for MS.
- Answer
-
Ministers and departmental officials have regular discussions with the National Institute for Health and Care Excellence (NICE) on a range of issues, including in relation to its guidelines.
NICE’s guideline on the diagnosis and management of multiple sclerosis in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with multiple sclerosis as it is not found to be a cost-effective treatment.
Secondary information
- Type
- Written question
- Reference
- 75791
- Session
- 2024-26
- Subjects
- Multiple sclerosis National Institute for Health and Care Excellence Fampridine
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2025-09-15 15:24:06 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/75791
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/75791
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/75791